## Paul M Coplan

## List of Publications by Citations

Source: https://exaly.com/author-pdf/5783508/paul-m-coplan-publications-by-citations.pdf

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

78 3,002 30 54 g-index

78 3,420 5.1 4.7 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
78	Hepatitis B vaccination and the risk of multiple sclerosis. <i>New England Journal of Medicine</i> , <b>2001</b> , 344, 327-32	59.2	292
77	Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. <i>Journal of Pain</i> , <b>2004</b> , 5, 344-56	5.2	238
76	International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. <i>Vaccine</i> , <b>2010</b> , 28, 950-7	4.1	201
75	Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. <i>Journal of Pain</i> , <b>2013</b> , 14, 351-8	5.2	149
74	The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. <i>Clinical Journal of Pain</i> , <b>2007</b> , 23, 490-6	3.5	124
73	Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. <i>AIDS Research and Human Retroviruses</i> , <b>2009</b> , 25, 483-8	1.6	119
72	Postmarketing evaluation of the safety and effectiveness of varicella vaccine. <i>Pediatric Infectious Disease Journal</i> , <b>1999</b> , 18, 1041-6	3.4	103
71	Development of a framework for enhancing the transparency, reproducibility and communication of the benefit-risk balance of medicines. <i>Clinical Pharmacology and Therapeutics</i> , <b>2011</b> , 89, 312-5	6.1	100
70	Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2013</b> , 22, 1274-82	2.6	96
69	Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010. <i>Journal of Pain</i> , <b>2013</b> , 14, 1122-30	5.2	84
68	Long-term effectiveness of varicella vaccine: a 14-Year, prospective cohort study. <i>Pediatrics</i> , <b>2013</b> , 131, e1389-96	7.4	82
67	Assessing the accuracy of opioid overdose and poisoning codes in diagnostic information from electronic health records, claims data, and death records. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2017</b> , 26, 509-517	2.6	75
66	Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women. <i>Aids</i> , <b>2009</b> , 23, 1531-8	3.5	70
65	Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents. <i>Journal of Infectious Diseases</i> , <b>2005</b> , 191, 1427-34	7	69
64	Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women. <i>AIDS Research and Human Retroviruses</i> , <b>2010</b> , 26, 1181-90	1.6	67
63	The role of herpes simplex virus type 2 and other genital infections in the acquisition of HIV-1 among high-risk women in northern Tanzania. <i>Journal of Infectious Diseases</i> , <b>2007</b> , 195, 1260-9	7	66
62	Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2014</b> , 23, 12	23 <del>8-</del> 46	59

## (2004-2008)

61	The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 9835-40	11.5	58
60	The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers. <i>Drug and Alcohol Dependence</i> , <b>2014</b> , 139, 9-17	4.9	56
59	Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial. <i>AIDS Research and Human Retroviruses</i> , <b>1999</b> , 15, 499-508	1.6	51
58	Impact of vaccination on the epidemiology of varicella: 1995-2009. <i>Pediatrics</i> , <b>2014</b> , 134, 24-30	7.4	49
57	The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting. <i>Clinical Pharmacology and Therapeutics</i> , <b>2016</b> , 100, 275-86	6.1	48
56	Adverse event assessment, analysis, and reporting in recent published analgesic clinical trials: ACTTION systematic review and recommendations. <i>Pain</i> , <b>2013</b> , 154, 997-1008	8	45
55	Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four different protease inhibitors. <i>AIDS Research and Human Retroviruses</i> , <b>2003</b> , 19, 449-55	1.6	45
54	Impact of an intervention to improve treatment-seeking behavior and prevent sexually transmitted diseases among Nigerian youths. <i>International Journal of Infectious Diseases</i> , <b>2003</b> , 7, 61-73	10.5	44
53	Incidence and hospitalization rates of varicella and herpes zoster before varicella vaccine introduction: a baseline assessment of the shifting epidemiology of varicella disease. <i>Pediatric Infectious Disease Journal</i> , <b>2001</b> , 20, 641-5	3.4	44
52	Understanding opioid overdose characteristics involving prescription and illicit opioids: A mixed methods analysis. <i>Drug and Alcohol Dependence</i> , <b>2016</b> , 167, 49-56	4.9	34
51	Public health. Regulatory challenges in microbicide development. <i>Science</i> , <b>2004</b> , 304, 1911-2	33.3	32
50	Is HIV drug resistance a limiting factor in the development of anti-HIV NNRTI and NRTI-based vaginal microbicide strategies?. <i>Antiviral Research</i> , <b>2006</b> , 71, 343-50	10.8	31
49	Predictors of herpes simplex virus type 2 prevalence and incidence among bar and hotel workers in Moshi, Tanzania. <i>Journal of Infectious Diseases</i> , <b>2007</b> , 195, 493-501	7	31
48	Identifying and classifying opioid-related overdoses: A validation study. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2019</b> , 28, 1127-1137	2.6	29
47	Perceptions of Sexual Behavior and Knowledge About Sexually Transmitted Diseases Among Adolescents in Benin City, Nigeria. <i>International Perspectives on Sexual and Reproductive Health</i> , <b>1999</b> , 25, 186		28
46	Oscillations in cell morphology and redox state. <i>Biophysical Chemistry</i> , <b>1990</b> , 37, 383-94	3.5	26
45	ER/LA Opioid Analgesics REMS: Overview of Ongoing Assessments of Its Progress and Its Impact on Health Outcomes. <i>Pain Medicine</i> , <b>2017</b> , 18, 78-85	2.8	24
44	A post-licensure evaluation of the safety of inactivated hepatitis A vaccine (VAQTA, Merck) in children and adults. <i>Vaccine</i> , <b>2004</b> , 22, 766-72	4.1	24

43	Monitoring of internet forums to evaluate reactions to the introduction of reformulated OxyContin to deter abuse. <i>Journal of Medical Internet Research</i> , <b>2014</b> , 16, e119	7.6	24
42	Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin). <i>Drug and Alcohol Dependence</i> , <b>2016</b> , 165, 221-8	4.9	23
41	Aggregating multiple real-world data sources using a patient-centered health-data-sharing platform. <i>Npj Digital Medicine</i> , <b>2020</b> , 3, 60	15.7	22
40	Discrepancies between registered and published primary outcome specifications in analgesic trials: ACTTION systematic review and recommendations. <i>Pain</i> , <b>2013</b> , 154, 2769-2774	8	21
39	Benefit-Risk Assessment, Communication, and Evaluation (BRACE) throughout the life cycle of therapeutic products: overall perspective and role of the pharmacoepidemiologist. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2015</b> , 24, 1233-40	2.6	19
38	Poor sensitivity of polymerase chain reaction assays of genital skin swabs and urine to detect HPV 6 and 11 DNA in men. <i>Sexually Transmitted Diseases</i> , <b>2003</b> , 30, 246-8	2.4	19
37	Cross-clade reactivity of HIV-1-specific T-cell responses in HIV-1-infected individuals from Botswana and Cameroon. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2006</b> , 42, 135-9	3.1	15
36	Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudine. <i>Clinical Infectious Diseases</i> , <b>2004</b> , 39, 426-33	11.6	15
35	Comparison of abuse, suspected suicidal intent, and fatalities related to the 7-day buprenorphine transdermal patch versus other opioid analgesics in the National Poison Data System. <i>Postgraduate Medicine</i> , <b>2017</b> , 129, 55-61	3.7	12
34	Using natural language processing of clinical text to enhance identification of opioid-related overdoses in electronic health records data. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2019</b> , 28, 1143-115	5 <del>2</del> .6	12
33	Indinavir did not increase the short-term risk of adverse cardiovascular events relative to nucleoside reverse transcriptase inhibitor therapy in four phase III clinical trials. <i>Aids</i> , <b>2001</b> , 15, 1584-6	3.5	12
32	Disproportionality analysis of buprenorphine transdermal system and cardiac arrhythmia using FDA and WHO postmarketing reporting system data. <i>Postgraduate Medicine</i> , <b>2017</b> , 129, 62-68	3.7	8
31	A retrospective cohort study of long-term immediate-release hydrocodone/acetaminophen use and acetaminophen dosing above the Food and Drug Administration recommended maximum daily limit among commercially insured individuals in the United States (2008-2013). <i>Journal of Pain</i> ,	5.2	7
30	Incidence of nonmedical use of OxyContin and other prescription opioid pain relievers before and after the introduction of OxyContin with abuse deterrent properties. <i>Postgraduate Medicine</i> , <b>2018</b> , 130, 568-574	3.7	7
29	Mathematical models and health economic aspects of microbicides. <i>Current Opinion in HIV and AIDS</i> , <b>2008</b> , 3, 587-92	4.2	7
28	Post-marketing evaluation of the short term safety of COMVAX. <i>Vaccine</i> , <b>2004</b> , 22, 536-43	4.1	7
27	Real-world outcomes of ventricular tachycardia catheter ablation with versus without intracardiac echocardiography. <i>Journal of Cardiovascular Electrophysiology</i> , <b>2020</b> , 31, 417-422	2.7	7
26	Adverse Event Reporting in Clinical Trials of Intravenous and Invasive Pain Treatments: An ACTTION Systematic Review. <i>Journal of Pain</i> , <b>2016</b> , 17, 1137-1149	5.2	7

## (2021-2020)

25	Postmarketing studies program to assess the risks and benefits of long-term use of extended-release/long-acting opioids among chronic pain patients. <i>Postgraduate Medicine</i> , <b>2020</b> , 132, 44-51	3.7	6
24	Development of an algorithm to identify inpatient opioid-related overdoses and oversedation using electronic data. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2019</b> , 28, 1138-1142	2.6	6
23	Trends in the diffusion of robotic surgery in prostate, uterus, and colorectal procedures: a retrospective population-based study. <i>Journal of Robotic Surgery</i> , <b>2021</b> , 15, 275-291	2.9	6
22	Assessing the impact of the extended-release/long-acting opioid an-algesics risk evaluation and mitigation strategies on opioid prescrip-tion volume. <i>Journal of Opioid Management</i> , <b>2017</b> , 13, 157-168	0.8	5
21	Carcinogenic hazard assessment of cobalt-containing alloys in medical devices: Review of in vivo studies. <i>Regulatory Toxicology and Pharmacology</i> , <b>2021</b> , 122, 104910	3.4	5
20	Indinavir did not further increase mean triglyceride levels in HIV-infected patients treated with nucleoside reverse transcriptase inhibitors: an analysis of three randomized clinical trials. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2003</b> , 12, 361-9	2.6	4
19	Challenges of evaluating and modelling vaccination in emerging infectious diseases. <i>Epidemics</i> , <b>2021</b> , 37, 100506	5.1	4
18	Evolving Treatment Patterns for Hospitalized COVID-19 Patients in the United States in April 2020-July 2020. <i>International Journal of General Medicine</i> , <b>2021</b> , 14, 267-271	2.3	4
17	Intracardiac echocardiography use and outcomes after catheter ablation of ventricular tachycardia. Journal of Comparative Effectiveness Research, <b>2020</b> , 9, 375-385	2.1	3
16	Protocol: changes in rates of opioid overdose and poisoning events in an integrated health system following the introduction of a formulation of OxyContin with abuse-deterrent properties. <i>BMC Pharmacology &amp; Dosicology</i> , <b>2016</b> , 17, 21	2.6	3
15	Abuse of reformulated OxyContin: Updated findings from a sentinel surveillance sample of individuals assessed for substance use disorder. <i>Journal of Opioid Management</i> , <b>2017</b> , 13, 425-440	0.8	3
14	Feasibility of capturing real-world data from health information technology systems at multiple centers to assess cardiac ablation device outcomes: A fit-for-purpose informatics analysis report. Journal of the American Medical Informatics Association: JAMIA, 2021, 28, 2241-2250	8.6	3
13	The selective toxicity of medications used in the treatment of AIDS on the CEM human leukemic CD4+ T-cell line. <i>Drug and Chemical Toxicology</i> , <b>1991</b> , 14, 257-64	2.3	2
12	The utility of real-world evidence for benefit-risk assessment, communication, and evaluation of pharmaceuticals: Case studies. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2020</b> , 29, 1532-1539	2.6	2
11	Using machine learning to predict post-operative depth of focus after cataract surgery with implantation of Tecnis Symfony. <i>European Journal of Ophthalmology</i> , <b>2021</b> , 31, 2938-2946	1.9	2
10	Controlling controlled substances abuse and misuse by managed care payers: a new generation of risk management initiatives?. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2014</b> , 23, 428-30	2.6	1
9	Comparative Safety of the TFN-ADVANCED Proximal Femoral Nailing System: Findings from a U.S. Health-Care Database. <i>Journal of Bone and Joint Surgery - Series A</i> , <b>2021</b> , 103, 1637-1645	5.6	1
8	Improving visual communication of discriminative accuracy for predictive models: the probability threshold plot. <i>JAMIA Open</i> , <b>2021</b> , 4, ooab017	2.9	1

7	Conditional power for assessing population interventions. <i>Journal of Comparative Effectiveness Research</i> , <b>2018</b> , 7, 1027-1035	2.1	1
6	Carcinogenic assessment of cobalt-containing alloys in medical devices or cobalt in occupational settings: A systematic review and meta-analysis of overall cancer risk from published epidemiologic studies. <i>Regulatory Toxicology and Pharmacology</i> , <b>2021</b> , 125, 104987	3.4	1
5	An integrated benefit-risk assessment of cobalt-containing alloys used in medical devices: Implications for regulatory requirements in the European Union. <i>Regulatory Toxicology and Pharmacology</i> , <b>2021</b> , 125, 105004	3.4	1
4	Feasibility of using real-world data in the evaluation of cardiac ablation catheters: a test-case of the National Evaluation System for Health Technology Coordinating Center <i>BMJ Surgery, Interventions, and Health Technologies</i> , <b>2021</b> , 3, e000089	1.2	1
3	Site-specific cancer risk following cobalt exposure via orthopedic implants or in occupational settings: A systematic review and meta-analysis <i>Regulatory Toxicology and Pharmacology</i> , <b>2021</b> , 129, 105096	3.4	О
2	Monthly trend in mortality and length of stay among coronavirus disease 2019 (COVID-19) patients: Analysis of a nationwide multihospital US database. <i>Infection Control and Hospital Epidemiology</i> , <b>2021</b> , 42, 1132-1135	2	O

Vaginal Microbicides Against HIV **2008**, 595-601